Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1834-4923 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Variations in Perioperative Thromboprophylaxis Practices: Do the Guidelines Need a Closer Look?
Ann Thorac Surg Short Rep
September 2024
Division of Thoracic Surgery, Department of Surgery, Hackensack Meridian Health Network, Hackensack, New Jersey.
Background: In 2022, the American Association for Thoracic Surgery (AATS) and the European Society of Thoracic Surgeons (ESTS) published joint guidelines regarding the timing, duration, and choice of agent for perioperative venous thromboembolism prophylaxis for thoracic cancer patients. Now, 1 year after their release, we looked to assess practices and general adherence to these recommendations.
Methods: We conducted a survey among board-certified/board-eligible thoracic surgeons in the United States, between July and October 2023.
The use of direct oral anticoagulants (DOACs) for thromboprophylaxis during neoadjuvant chemotherapy and after interval debulking surgery in ovarian cancer patients - Maximizing prevention of venous thromboembolism (VTE).
Gynecol Oncol Rep
December 2024
The University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, United States.
Prophylactic direct oral anticoagulants vs. low molecular weight heparin after urological surgery: A systematic review and meta-analysis.
Arab J Urol
September 2024
Department of Surgery, Sabah Al-Ahmad Urology Center, Kuwait City, Kuwait.
Purpose: To compare the outcomes of using prophylactic direct oral anti-coagulants (DOAC) and low-molecular-weight heparin (LMWH) after major urologic surgery.
Materials And Methods: Systematic literature searches of MEDLINE, Embase, Web of Science, and Cochrane CENTRAL were performed up to 9 November 2023, and protocols were registered on PROSPERO (CRD42024494424). The primary outcomes were post-operative incidence of VTE and bleeding.
Danaparoid-Consensus Recommendations on Its Clinical Use.
Pharmaceuticals (Basel)
November 2024
Independent Researcher, 5345 MT Oss, The Netherlands.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.
View Article and Find Full Text PDFDetermining the perceptions and practices of oncologists regarding venous thromboembolism risk assessment in ambulatory cancer patients: A qualitative study.
PLoS One
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
Cancer-associated thrombosis (CAT) can increase morbidity and mortality for cancer patients. Therefore, guidelines recommend predicting VTE risk and thromboprophylaxis for high-risk patients. Many studies critique oncologists' adherence to thromboprophylaxis guidelines for cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!